NCT06780033 - A Study to Evaluate ART101 in Adult Participants With Hypertension | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 17, 2025

Primary Completion Date

April 30, 2025

Study Completion Date

April 30, 2025

Conditions

Hypertension

Interventions

DRUG

ART-101 - SAD

Forty participants will be enrolled across 5 SAD cohorts. The planned doses across 5 cohorts are as follows- include 20mg (SAD Cohort 1), 60mg (SAD Cohort 2). 150mg (SAD Cohort 3). 300mg (SAD Cohort 4) and 500 mg (SAD Cohort 5).

OTHER

Placebo

Participants will receive matching placebo subcutaneously on Day 1 after 8 hour fast.

Trial Locations (3)

4506

University of Sunshine Coast, Morayfield

5000

CMAX Clinical Research Central, Adelaide

5067

CMAX Clinical Research Fusion, Norwood